ストックスクリーナーアプリを入手
523.15
0.91%
-5.7527
前日終値:
$528.90
開ける：
$524
24時間の取引高:
124.56K
Relative Volume:
0.09
時価総額：
$132.56B
収益：
$12.34B
当期純損益:
$4.34B
株価収益率:
31.01
EPS:
16.8685
ネットキャッシュフロー:
$3.71B
1週間 パフォーマンス:
-5.87%
1か月 パフォーマンス:
+5.65%
6か月 パフォーマンス:
+13.72%
1年 パフォーマンス:
+32.19%
1日の値動き範囲:
$520.08
$528.16
1週間の範囲:
$520.08
$560.25
52週間の値動き範囲:
$374.17
$560.25
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
523.00 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.20 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.04 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.94 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.37 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | アップグレード | Maxim Group | Hold → Buy |
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-03-10 | 繰り返されました | Oppenheimer | Outperform |
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Where does Vertex Pharmaceuticals (NASDAQ:VRTX) fit within the Healthcare stocks conversation? - Kalkine Media
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution - Seeking Alpha
Vertex Pharma stock heads into the open after a 3.1 percent drop - AD HOC NEWS
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send? - TradingKey
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock - The Motley Fool
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Why CRISPR Therapeutics Stock Rocked the Market Last Month - The Motley Fool
Vertex Pharmaceuticals stock edges lower as market digests strong Q2 figures and insider selling - AD HOC NEWS
Vertex shares fall as investors digest Crinetics acquisition and related financing plans - Quiver Quantitative
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Could Nasdaq Focus Lift Attention on Vertex Pharmaceuticals (NASDAQ:VRTX)? - Kalkine Media
Vertex Pharmaceuticals stock steadies near a 52-week high - AD HOC NEWS
Why Vertex stock is sliding today - Wealth Awesome
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Titan with 4.29% Upside and Robust Buy Ratings - DirectorsTalk Interviews
Vertex Pharma stock slips as revenue and EPS stay in view - AD HOC NEWS
Vertex makes some big people moves, completes its largest acquisition - The Boston Globe
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout - Fierce Biotech
Is Vertex Pharmaceuticals (VRTX) Undervalued Following Casgevy’s FDA Label Expansion? - simplywall.st
Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion By Investing.com - Investing.com Canada
Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - Fierce Biotech
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ) - Seeking Alpha
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report? - Yahoo Finance
Vertex Pharmaceuticals stock hits all-time high at $555.84 By Investing.com - Investing.com Canada
Vertex Pharmaceuticals stock hits all-time high at $555.84 - Investing.com India
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Appoints Jonathan Poole as New Chi - GuruFocus
Crinetics Director Stephanie Okey Sells All Shares Following Vertex Pharmaceuticals Merger - Kalkine Media
Crinetics Director Wendell Wierenga Reports Stock Disposals Following Vertex Merger - Kalkine Media
Vertex buyout pays Crinetics (CRNX) insider in cash, but his options fared very differently - Stock Titan
Crinetics (NASDAQ: CRNX) director’s stock, options and RSUs all vest and turn to cash in Vertex buyout - Stock Titan
Crinetics (NASDAQ: CRNX) CCO awards vest, then are cashed out or wiped in $85-a-share Vertex merger - Stock Titan
Takeover hands Crinetics (CRNX) science chief an $85-a-share cash exit - Stock Titan
Vertex’s $85 deal cashes out Crinetics (NASDAQ: CRNX) awards - Stock Titan
Crinetics (CRNX) shareholders receive $85 per share as Vertex takeover closes - Stock Titan
Vertex (NASDAQ: VRTX) records new insider stock transaction - Stock Titan
Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027 - marketscreener.com
Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds - Yahoo Finance
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform - Yahoo Finance
Vertex Completes $10 Billion Acquisition of Crinetics at $85 Per Share - Minichart
Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes - marketscreener.com
Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition - marketscreener.com
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team - Business Wire
Vertex (NASDAQ: VRTX) director gifts 6,000 shares - Stock Titan
Shareholder approval clears way for Crinetics (NASDAQ: CRNX) sale to Vertex - Stock Titan
Vertex (NASDAQ: VRTX) director to sell $663K in shares via charity - Stock Titan
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
1.23%
大文字化:
|
ボリューム (24 時間):